Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy
This article was originally published in The Gray Sheet
Despite a recent negative Blue Cross Blue Shield technology assessment, Neuronetics is moving ahead with plans to expand sales and marketing efforts for its NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression.
You may also be interested in...
Neuronetics releases long-term data on NeuroStar TMS therapy for depression. Bayesian methods confirm stenting matches surgery in patients with unprotected left-main disease. More research briefs.
Latest news from the Medicare agency and other payers.
User fees to go down next year